The Quantellect read.As of Nov 19, 2026, 13 active firms cover Hims Hers Health Inc: 3 rate it Buy or better, 10 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets range widely, $24.00 to $60.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $33.77 sits 107% above the current $16.31. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Neutral
Strong Buy00%
Buy323%
Neutral1077%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.77
+107.0% upside
Average target across 13 active firms as of Nov 19, 2026 vs $16.31 current
Highest Target$60.00
Average Target$33.77
Lowest Target$24.00
Detailed analyst forecasts for HIMS
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 3 of 13 active firms rate HIMS a Buy (10 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HIMS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.20 – $0.01 · 4 analysts · -84% YoY
Next period, 4 analysts expect Hims Hers Health Inc to earn $-0.06 a share (range $-0.20 – $0.01), versus $-0.40 a year earlier. Full-year consensus is $-0.91, growing to $-0.07 the year after.
REVENUE · NEXT QUARTER
$904.1M
Range $860.9M – $953.5M · 4 analysts · +49% YoY
Revenue is expected to reach $904.1M (range $860.9M – $953.5M), +48.7% year-over-year. Full-year consensus is $3.1B, rising to $3.9B next year.
Top analysts covering Hims Hers Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HIMS.
#1
Brian Tanquilut
Jefferies · Rank #280
Neutral
$24.00+47.1% to target
Overall win rate
46%
+ Follow
#2
Justin Patterson
Keybanc · Rank #505
Neutral
No targeton HIMS
Overall win rate
30%
+ Follow
#3
Ryan MacDonald
Needham · Rank #579
Buy
$32.00+96.2% to target
Overall win rate
19%
+ Follow
#4
Allen Lutz
B of A Securities
Neutral
$32.00+96.2% to target
Coverage
—
+ Follow
#5
GS
Glen Santangelo
Barclays
Buy
$35.00+114.6% to target
Coverage
—
+ Follow
HIMS stock forecast FAQ
What is HIMS's average 12-month price target?+
The 13 active firms with a live target average $33.77 for Hims Hers Health Inc over the next 12 months, ranging from a $60.00 high to a $24.00 low, as of Nov 19, 2026.
Is HIMS stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 13 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 10 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HIMS?+
The Street-high target is $60.00, and the Street-low is $24.00 (Evercore ISI Group). The average of all 13 active-firm targets is $33.77.
How many active Wall Street firms cover HIMS?+
13 active firms have a recognized rating on Hims Hers Health Inc as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HIMS?+
Among analysts who currently cover HIMS, Brian Tanquilut of Jefferies has the strongest overall Quantellect track record (Rank #280). Their current call is Neutral with a $24.00 target.
What is Hims Hers Health Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.20 – $0.01) across 4 analysts. Full-year EPS is projected at $-0.91, rising to $-0.07 the following year.
How much revenue is Hims Hers Health Inc expected to report next quarter?+
Consensus revenue is $904.1M (range $860.9M – $953.5M). Full-year revenue is projected at $3.1B, growing to $3.9B next year.
Have analysts been upgrading or downgrading HIMS lately?+
As of Nov 19, 2026, 3 of 13 active firms rate HIMS a Buy (10 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HIMS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.